Cost Curve

What the White House’s Vastly Inflated MFN Savings Numbers Really Tell Us

Brian Reid

Running the Numbers on Pharm-to-Table in Obesity, Cholesterol Management

And industry gets a win in a 340B “STD loophole” case

Brian Reid

Maine Is a Battleground State. Cue the Less-Than-Constructive Healthcare Ads.

And there is bipartisan consensus on the most divisive issue in health care [sic]

Brian Reid

Are Pharma CEOs Talking MFN During Earnings Season? Depends On Who You Ask.

Plus, launching the quarterly Apex tracker of CEO earnings commentary

Brian Reid

Prescriptions for an 11-Year-Old Drug for Female Libido Just Doubled, and Pharm-to-Table Played a Role

And Elizabeth Warren’s inquiry into TrumpRx asks the exact questions I’m interested in

Brian Reid

It’s Increasingly Clear That MFN Will Impact Europe First

And the votes are in on the “healthcare” vs “health care” debate ...

Brian Reid

Regeneron’s Free Gene Therapy, Six New Meds to TrumpRx (and One to Mark Cuban), and the Ten Other Stories to Track Today

And I need your vote on an issue of huge significance

Brian Reid

APEX Special Edition: 340B Is Having a Week. These 10 Stories Prove It.

Brian Reid

The Three Most Interesting Things RFK Jr. Said About Drug Prices This Week

And we know that CMS will pay for obesity meds in Medicare through 2027. But what about 2028 ... and beyond?

Brian Reid